Research programme: targeted cancer diagnostics - Cancer Targeted Technology/GE Healthcare
Latest Information Update: 20 Dec 2010
At a glance
- Originator CTT Cancer Targeting Technologies; GE Healthcare
- Class Cyclic peptides
- Mechanism of Action Gelatinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Dec 2010 Discontinued - Preclinical for Cancer in Finland (unspecified route)
- 10 Nov 2006 Preclinical trials in Diagnostic imaging in Finland (unspecified route)